Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
NCT00409188
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Nebraska Cancer Care, LLC, Hastings, Nebraska +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
NCT00715208
Completed
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone (VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone (VELCADE-R-CP) based on investigator preference. Following completion of the treatment period, patients will receive maintenance therapy with rituxi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2013
Locations: Nebraska Hematology-Oncology, PC, Lincoln, Nebraska +1 locations
Conditions: Relapsed Follicular Lymphoma
Register for Updates